AU2002316499B2 - Aryl boronic acids for treating obesity - Google Patents
Aryl boronic acids for treating obesity Download PDFInfo
- Publication number
- AU2002316499B2 AU2002316499B2 AU2002316499A AU2002316499A AU2002316499B2 AU 2002316499 B2 AU2002316499 B2 AU 2002316499B2 AU 2002316499 A AU2002316499 A AU 2002316499A AU 2002316499 A AU2002316499 A AU 2002316499A AU 2002316499 B2 AU2002316499 B2 AU 2002316499B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- substituted
- sub
- straight chained
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 21
- 235000020824 obesity Nutrition 0.000 title claims abstract description 21
- 150000001543 aryl boronic acids Chemical class 0.000 title description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 56
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 38
- 150000001412 amines Chemical class 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 23
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 20
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000006575 electron-withdrawing group Chemical group 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
- 150000002367 halogens Chemical class 0.000 claims abstract description 11
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 10
- 150000003568 thioethers Chemical class 0.000 claims abstract description 10
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- 125000005647 linker group Chemical group 0.000 claims abstract description 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract description 6
- 125000005496 phosphonium group Chemical group 0.000 claims abstract description 5
- 150000003573 thiols Chemical class 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 34
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N dihydroxy-phenylborane Natural products OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 19
- -1 phenyl boronic acid compound Chemical class 0.000 abstract description 19
- 239000000243 solution Substances 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 239000002904 solvent Substances 0.000 description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 238000003756 stirring Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- 229920000642 polymer Polymers 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 102000004882 Lipase Human genes 0.000 description 13
- 108090001060 Lipase Proteins 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 12
- 239000004367 Lipase Substances 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 235000019421 lipase Nutrition 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229940127470 Lipase Inhibitors Drugs 0.000 description 10
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 8
- 229940117969 neopentyl glycol Drugs 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000005620 boronic acid group Chemical group 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940040461 lipase Drugs 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- ULGGZAVAARQJCS-UHFFFAOYSA-N 11-sulfanylundecan-1-ol Chemical compound OCCCCCCCCCCCS ULGGZAVAARQJCS-UHFFFAOYSA-N 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229940086609 Lipase inhibitor Drugs 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000004130 lipolysis Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000013585 weight reducing agent Substances 0.000 description 4
- QJJKXFKEZBWZHN-UHFFFAOYSA-N B1OSO1 Chemical compound B1OSO1 QJJKXFKEZBWZHN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- GVXYQPSIVLTOJD-UHFFFAOYSA-N [4-(2-bromoacetyl)-2,5-difluorophenyl]boronic acid Chemical compound OB(O)C1=CC(F)=C(C(=O)CBr)C=C1F GVXYQPSIVLTOJD-UHFFFAOYSA-N 0.000 description 3
- BQZTUNUYGFMPBU-UHFFFAOYSA-N [4-(2-bromoacetyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(=O)CBr)C=C1 BQZTUNUYGFMPBU-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 150000001642 boronic acid derivatives Chemical class 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- YHEPWJRNHLTYSL-UHFFFAOYSA-N (4-acetyl-3-fluorophenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1F YHEPWJRNHLTYSL-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- BXVHKBNJUHSCRF-UHFFFAOYSA-N [4-(2-bromoacetyl)-3-fluorophenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(=O)CBr)C(F)=C1 BXVHKBNJUHSCRF-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 150000003613 toluenes Chemical class 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229940002552 xenical Drugs 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- JPTNTBSBJPCXGI-UHFFFAOYSA-N 1-(4-bromo-2,5-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC(F)=C(Br)C=C1F JPTNTBSBJPCXGI-UHFFFAOYSA-N 0.000 description 1
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- IGBZCOWXSCWSHO-UHFFFAOYSA-N 1-(5-bromothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC=C(Br)S1 IGBZCOWXSCWSHO-UHFFFAOYSA-N 0.000 description 1
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 1
- WSULSMOGMLRGKU-UHFFFAOYSA-N 1-bromooctadecane Chemical compound CCCCCCCCCCCCCCCCCCBr WSULSMOGMLRGKU-UHFFFAOYSA-N 0.000 description 1
- ZNJOCVLVYVOUGB-UHFFFAOYSA-N 1-iodooctadecane Chemical compound CCCCCCCCCCCCCCCCCCI ZNJOCVLVYVOUGB-UHFFFAOYSA-N 0.000 description 1
- KPDJJZWPGVIVNI-UHFFFAOYSA-M 10-bromodecyl(trimethyl)azanium;1,10-dibromodecane;bromide Chemical compound [Br-].BrCCCCCCCCCCBr.C[N+](C)(C)CCCCCCCCCCBr KPDJJZWPGVIVNI-UHFFFAOYSA-M 0.000 description 1
- XFGANBYCJWQYBI-UHFFFAOYSA-N 11-bromoundecan-1-ol Chemical compound OCCCCCCCCCCCBr XFGANBYCJWQYBI-UHFFFAOYSA-N 0.000 description 1
- GWOLZNVIRIHJHB-UHFFFAOYSA-N 11-mercaptoundecanoic acid Chemical compound OC(=O)CCCCCCCCCCS GWOLZNVIRIHJHB-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- MDNDJMCSXOXBFZ-UHFFFAOYSA-N 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane Chemical compound O1CC(C)(C)COB1B1OCC(C)(C)CO1 MDNDJMCSXOXBFZ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- VKRHTRDIFQXUSJ-UHFFFAOYSA-N 2-borono-5-(11-hydroxyundecyl)benzoic acid Chemical compound OCCCCCCCCCCCC1=CC=C(B(O)O)C(C(O)=O)=C1 VKRHTRDIFQXUSJ-UHFFFAOYSA-N 0.000 description 1
- XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 1
- DBVFWZMQJQMJCB-UHFFFAOYSA-N 3-boronobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1 DBVFWZMQJQMJCB-UHFFFAOYSA-N 0.000 description 1
- NNZGNZHUGJAKKT-UHFFFAOYSA-M 3-bromopropyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCBr NNZGNZHUGJAKKT-UHFFFAOYSA-M 0.000 description 1
- YUHCOUPKUNJQIC-UHFFFAOYSA-N 4-(3-chloropropyl)octadecyl-dimethylazanium bromide Chemical compound [Br-].CCCCCCCCCCCCCCC(CCCCl)CCC[NH+](C)C YUHCOUPKUNJQIC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- YANFFNKCIXBHDU-UHFFFAOYSA-N [4-(dioctadecylcarbamoyl)phenyl]boronic acid Chemical compound CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)C(=O)C1=CC=C(B(O)O)C=C1 YANFFNKCIXBHDU-UHFFFAOYSA-N 0.000 description 1
- RKVCIHSKQLKLDQ-UHFFFAOYSA-N [Br-].[Br-].C[NH+](C)C.C[NH+](C)C Chemical compound [Br-].[Br-].C[NH+](C)C.C[NH+](C)C RKVCIHSKQLKLDQ-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- TVAVIKKWTBSOPJ-UHFFFAOYSA-N docosyl methanesulfonate Chemical compound CCCCCCCCCCCCCCCCCCCCCCOS(C)(=O)=O TVAVIKKWTBSOPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
- HKUFIYBZNQSHQS-UHFFFAOYSA-N n-octadecyloctadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC HKUFIYBZNQSHQS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30208101P | 2001-06-29 | 2001-06-29 | |
| US60/302,081 | 2001-06-29 | ||
| US35946702P | 2002-02-22 | 2002-02-22 | |
| US60/359,467 | 2002-02-22 | ||
| PCT/US2002/020923 WO2003002570A1 (en) | 2001-06-29 | 2002-07-01 | Aryl boronic acids for treating obesity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005220192A Division AU2005220192A1 (en) | 2001-06-29 | 2005-10-05 | Aryl boronic acids for treating obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002316499A1 AU2002316499A1 (en) | 2003-05-15 |
| AU2002316499B2 true AU2002316499B2 (en) | 2005-08-04 |
Family
ID=26972758
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002316499A Ceased AU2002316499B2 (en) | 2001-06-29 | 2002-07-01 | Aryl boronic acids for treating obesity |
| AU2005220192A Abandoned AU2005220192A1 (en) | 2001-06-29 | 2005-10-05 | Aryl boronic acids for treating obesity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005220192A Abandoned AU2005220192A1 (en) | 2001-06-29 | 2005-10-05 | Aryl boronic acids for treating obesity |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6858592B2 (https=) |
| EP (1) | EP1404685B1 (https=) |
| JP (1) | JP2004535452A (https=) |
| AT (1) | ATE339426T1 (https=) |
| AU (2) | AU2002316499B2 (https=) |
| CA (1) | CA2489681A1 (https=) |
| CY (1) | CY1105829T1 (https=) |
| DE (1) | DE60214713T2 (https=) |
| DK (1) | DK1404685T3 (https=) |
| ES (1) | ES2275888T3 (https=) |
| PT (1) | PT1404685E (https=) |
| WO (1) | WO2003002570A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US6858592B2 (en) * | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| AU2003223930A1 (en) * | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
| AU2003291567A1 (en) * | 2002-11-19 | 2004-06-15 | Genzyme Corporation | Polymeric boronic acid derivatives as lipase inhibitors |
| KR20070086076A (ko) * | 2004-11-12 | 2007-08-27 | 트러스티즈 오브 터프츠 칼리지 | 리파아제 억제제 |
| EP1867650B1 (en) * | 2005-03-14 | 2012-06-27 | Eisai R&D Management Co., Ltd. | Hydroxymethylboron compounds |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| US10157355B2 (en) | 2005-11-15 | 2018-12-18 | General Electric Company | Method to view schedule interdependencies and provide proactive clinical process decision support in day view form |
| US7801058B2 (en) * | 2006-07-27 | 2010-09-21 | Mobitrum Corporation | Method and system for dynamic information exchange on mesh network devices |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2009012596A1 (en) * | 2007-07-24 | 2009-01-29 | The University Of British Columbia | Substituted aryl-fluoroborates as imaging agents |
| CA2721060A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8709489B2 (en) | 2009-09-30 | 2014-04-29 | Surmodics, Inc. | Emulsions containing arylboronic acids and medical articles made therefrom |
| RU2015143910A (ru) | 2010-02-03 | 2018-12-28 | Инфинити Фармасьютикалз, Инк. | Ингибиторы амид-гидролазы жирных кислот |
| US8546617B1 (en) | 2012-03-23 | 2013-10-01 | Empire Technology Development Llc | Dioxaborinanes and uses thereof |
| IN2015DN00805A (https=) * | 2012-07-31 | 2015-07-03 | Empire Technology Dev Llc | |
| US9120938B2 (en) | 2012-07-31 | 2015-09-01 | Empire Technology Development Llc | Polymerizable organoboron alkyd resin anti fouling coatings |
| ES2618374T3 (es) * | 2012-10-17 | 2017-06-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Composiciones y métodos para mejorar la absorción de glucosa |
| WO2014134716A1 (en) | 2013-03-08 | 2014-09-12 | The University Of British Columbia | Substituted organofluoroborates as imaging agents |
| EP3362462B1 (en) | 2015-10-12 | 2021-07-21 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
| CN106243343B (zh) * | 2016-08-11 | 2018-04-03 | 江苏大学 | 一种苯硼酸功能化嵌段聚合物的合成及应用 |
| US12427209B2 (en) | 2018-12-18 | 2025-09-30 | Provincial Health Services Authority | Dual mode 18F-labelled theranostic compounds and uses thereof |
| TW202304469A (zh) * | 2021-03-24 | 2023-02-01 | 美商杜夫特學院信託管理公司 | 酸化合物、組合物及方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702952A (en) * | 1994-03-31 | 1997-12-30 | Axis Biochemicals Asa | Labelled boronic acid derivatives |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4496722A (en) | 1981-05-01 | 1985-01-29 | The Children's Medical Center Corporation | Reporter compounds |
| GB8819224D0 (en) | 1988-08-12 | 1988-09-14 | Merck Patent Gmbh | Process for preparation of rod-like compounds |
| DE3930663C1 (en) | 1989-09-14 | 1990-11-15 | Merck Patent Gmbh, 6100 Darmstadt, De | Cross-coupling metal organic cpds. and e.g. halogen cpds. - includes using transition metal-palladium catalyst and opt. metal alcoholate |
| EP0478050A1 (en) | 1990-09-24 | 1992-04-01 | Unilever N.V. | Detergent composition |
| GB9024775D0 (en) | 1990-11-14 | 1991-01-02 | Axis Research | Chemical compounds |
| IE914573A1 (en) | 1991-01-17 | 1992-07-29 | Ici Plc | Boron compounds |
| DE69206795T2 (de) | 1991-04-30 | 1996-09-05 | Procter & Gamble | ARYLBORONSäURE ENTHALTENDE FLüSSIGWASCHMITTEL |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| CH683522A5 (de) | 1992-03-13 | 1994-03-31 | Hoffmann La Roche | Verfahren zur Herstellung von Diarylen. |
| JP3257029B2 (ja) | 1992-04-22 | 2002-02-18 | 日本油脂株式会社 | フェニルボロン酸誘導体及び製造方法 |
| CA2096496A1 (en) | 1992-05-29 | 1993-11-30 | Bradley C. Pearce | Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia |
| US5290817A (en) | 1992-06-09 | 1994-03-01 | The Du Pont Merck Pharmaceutical Co. | Substituted 1-benzylindanes and their use as inhibitors of phospholipase A2 |
| DE69330069D1 (en) | 1992-12-21 | 2001-05-03 | Syngenta Ltd | Chinuclidin derivate als squalen synthase inhibitoren |
| GB2276162A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benazilide derivatives |
| JP3894949B2 (ja) | 1993-06-30 | 2007-03-22 | ザ、ウェルカム、ファンデーション、リミテッド | 抗アテローム性動脈硬化症ジアリール化合物 |
| WO1995002046A1 (en) | 1993-07-09 | 1995-01-19 | Novo Nordisk A/S | Boronic acid or borinic acid derivatives as enzyme stabilizers |
| JP3412198B2 (ja) * | 1993-08-31 | 2003-06-03 | 日本油脂株式会社 | 変性マレイン酸共重合体および用途 |
| WO1995011243A1 (en) | 1993-10-19 | 1995-04-27 | Smithkline Beecham Plc | Benzanilide derivatives as 5ht-1d receptor antagonists |
| JPH09508373A (ja) | 1994-01-27 | 1997-08-26 | チバーガイギー アクチェンゲゼルシャフト | パラジウム触媒による交差カップリング反応を経由するアリール酢酸エステル誘導体の製造方法 |
| SI9400289A (en) | 1994-07-13 | 1996-02-29 | Ponikvar Jadranka Buturovic | A method for preventing blood coagulation in a haemodialysis circuit or haemodialysis analogy procedure in the extra-body circuit. |
| WO1996017833A1 (en) | 1994-12-09 | 1996-06-13 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| WO1996021716A1 (en) | 1995-01-09 | 1996-07-18 | Novo Nordisk A/S | Stabilization of liquid enzyme compositions |
| AU5147196A (en) | 1995-03-27 | 1996-10-16 | Smithkline Beecham Plc | Bicyclic amine derivatives and their use as anti-psychotic a gents |
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| DE69621131T2 (de) | 1995-06-13 | 2002-11-28 | Novozymes A/S, Bagsvaerd | 4-substituierte-phenylboronsäuren als enzymstabilisatoren |
| US5631371A (en) | 1995-11-22 | 1997-05-20 | Bayer Corporation | Method for the preparation of substituted 3-(phenylimino)-3H-phenothiazines and phenoxazines |
| GB9603137D0 (en) | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
| WO1998022820A1 (en) | 1996-11-21 | 1998-05-28 | Lawrence Livermore National Laboratory | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
| EP0975614A1 (en) | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| AU8140898A (en) | 1997-06-13 | 1998-12-30 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
| EP1000031A4 (en) | 1997-07-25 | 2001-08-16 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
| CO5011067A1 (es) | 1997-11-03 | 2001-02-28 | Novartis Ag | Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen |
| US6264937B1 (en) | 1998-01-09 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| CA2321791A1 (en) | 1998-03-18 | 1999-09-23 | Ciba Specialty Chemicals Holding Inc. | Coupling reactions with palladium catalysts |
| AU5235599A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | N-substituted sulfonamide derivatives |
| DE69919179T2 (de) | 1998-09-09 | 2005-07-28 | Inflazyme Pharmaceuticals, Ltd., Richmond | Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| DE19857765A1 (de) | 1998-12-15 | 2000-06-21 | Clariant Gmbh | Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren |
| WO2000035904A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| WO2000042213A1 (en) | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
| BRPI0011172B8 (pt) | 1999-04-14 | 2021-05-25 | Pacific Corp | derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2 |
| JP4507294B2 (ja) | 1999-05-27 | 2010-07-21 | チッソ株式会社 | ビアリール誘導体の製造方法 |
| CA2315614C (en) | 1999-07-29 | 2004-11-02 | Pfizer Inc. | Pyrazoles |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| EP1889891B1 (en) | 2000-11-30 | 2017-11-22 | Canon Kabushiki Kaisha | Luminescence device and display apparatus |
| JP3589450B2 (ja) | 2001-03-13 | 2004-11-17 | 独立行政法人 科学技術振興機構 | アミド脱水縮合触媒として有用なパーフルオロアルキルフェニルホウ酸 |
| US6858592B2 (en) * | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
| AU2003243594A1 (en) | 2002-06-13 | 2003-12-31 | Johns Hopkins University | Novel boronic chalcone derivatives and uses thereof |
| US7045652B2 (en) * | 2002-07-03 | 2006-05-16 | Pfizer Inc | Processes for preparing substituted aryl boronic acids |
-
2002
- 2002-06-27 US US10/187,397 patent/US6858592B2/en not_active Expired - Lifetime
- 2002-07-01 AU AU2002316499A patent/AU2002316499B2/en not_active Ceased
- 2002-07-01 JP JP2003508951A patent/JP2004535452A/ja active Pending
- 2002-07-01 CA CA002489681A patent/CA2489681A1/en not_active Abandoned
- 2002-07-01 AT AT02746808T patent/ATE339426T1/de not_active IP Right Cessation
- 2002-07-01 PT PT02746808T patent/PT1404685E/pt unknown
- 2002-07-01 WO PCT/US2002/020923 patent/WO2003002570A1/en not_active Ceased
- 2002-07-01 DE DE60214713T patent/DE60214713T2/de not_active Expired - Fee Related
- 2002-07-01 ES ES02746808T patent/ES2275888T3/es not_active Expired - Lifetime
- 2002-07-01 EP EP02746808A patent/EP1404685B1/en not_active Expired - Lifetime
- 2002-07-01 DK DK02746808T patent/DK1404685T3/da active
-
2004
- 2004-12-30 US US11/027,643 patent/US7049304B2/en not_active Expired - Lifetime
-
2005
- 2005-10-05 AU AU2005220192A patent/AU2005220192A1/en not_active Abandoned
-
2006
- 2006-01-31 US US11/343,598 patent/US7456156B2/en not_active Expired - Fee Related
- 2006-12-05 CY CY20061101748T patent/CY1105829T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702952A (en) * | 1994-03-31 | 1997-12-30 | Axis Biochemicals Asa | Labelled boronic acid derivatives |
Non-Patent Citations (2)
| Title |
|---|
| Angew. Chem., vol.11 (1999) pp.3250-3253 * |
| J. Org. Chem. vol.67, no.1 (2001) pp.3-15 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003002570A1 (en) | 2003-01-09 |
| ES2275888T3 (es) | 2007-06-16 |
| US7456156B2 (en) | 2008-11-25 |
| US20030064963A1 (en) | 2003-04-03 |
| DE60214713D1 (de) | 2006-10-26 |
| CA2489681A1 (en) | 2003-01-09 |
| US20060128664A1 (en) | 2006-06-15 |
| US7049304B2 (en) | 2006-05-23 |
| JP2004535452A (ja) | 2004-11-25 |
| CY1105829T1 (el) | 2011-02-02 |
| EP1404685B1 (en) | 2006-09-13 |
| US6858592B2 (en) | 2005-02-22 |
| AU2005220192A1 (en) | 2005-12-01 |
| PT1404685E (pt) | 2007-01-31 |
| HK1065046A1 (en) | 2005-02-08 |
| DK1404685T3 (da) | 2007-01-22 |
| ATE339426T1 (de) | 2006-10-15 |
| EP1404685A1 (en) | 2004-04-07 |
| US20050107336A1 (en) | 2005-05-19 |
| DE60214713T2 (de) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002316499B2 (en) | Aryl boronic acids for treating obesity | |
| AU2002316499A1 (en) | Aryl Boronic Acids For Treating Obesity | |
| JP3231043B2 (ja) | 薬理活性を有する硝酸エステルおよびその製法 | |
| US4851426A (en) | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids and pharmaceutical compositions thereof | |
| JP3631755B2 (ja) | ポリオキシエチレン含有脂質二本鎖誘導体 | |
| AU4913396A (en) | High molecular weight polymer-based prodrugs | |
| AU2002318470B2 (en) | Aryl boronate functionalized polymers for treating obesity | |
| CN103626825B (zh) | 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途 | |
| AU2002318470A1 (en) | Aryl boronate functionalized polymers for treating obesity | |
| JP3781877B2 (ja) | アスコルビン酸誘導体またはその塩、および医薬 | |
| Husain | Amide Derivatives of Sulfonamides and Isoniazid: Synthesis and Biological Evaluationü | |
| CN1042131C (zh) | N－肉桂酰基－2－甲基－5－甲氧基－3－吲哚乙酸酯、其制备方法及含有这种化合物的药物组合物 | |
| US5196567A (en) | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | |
| HK1065046B (en) | Aryl boronic acids for treating obesity | |
| CN116813515A (zh) | 一种姜黄素衍生物前药、其制备方法和应用 | |
| CN109847067B (zh) | 一种双氯芬酸-甘氨酸-白藜芦醇偶联物、制备方法及应用 | |
| CN101293954A (zh) | 聚氧乙烯-聚氧丙烯-聚氧乙烯共聚物羧基化方法 | |
| CN114426538A (zh) | 一种小檗碱卡格列净衍生物及其制备方法和应用 | |
| CN101974150A (zh) | 含布洛芬端基的聚乙二醇药物大单体及其合成方法 | |
| KR890003624B1 (ko) | 경구용 피페라실린 피발로일옥시메틸 에스테르의 제조방법 | |
| CN116410249A (zh) | β-葡萄糖醛酸苷酶响应型微管蛋白聚集抑制剂前药及其制备方法与用途 | |
| JPS59152348A (ja) | ビフエニリルプロピオン酸エステル誘導体およびその製造法 | |
| HK1020333A (en) | Polyol succinates and their pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |